Dynamics of tumour hypoxia and metabolism during Chemoradiotherapy for stage III Non Small Cell Lung Cancer, using 18F-FAZA-PET/CT and 18F-FDG-PET/CT. A Pilot Study
Completed
- Conditions
- non-small-cell-lung-cancer10038666
- Registration Number
- NL-OMON39397
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
- WHO PS 0-2
- Histological or cytological confirmation of non-small cell lung cancer.
- Stage IIIA or IIIB
- Adequate pulmonary function estimated by flow volume curves
- Life expectancy of at least 6 months
- Planned for 25 x 2.4 Gy 3DCRT, with concomitant chemotherapy
Exclusion Criteria
- Other stages than stage III NSCLC
- PS > 2
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Assessing tumour hypoxia using 18F-FAZA-PET/CT for stage III NSCLC during<br /><br>curative chemoradiotherapy</p><br>
- Secondary Outcome Measures
Name Time Method <p>To investigate tumour heterogeneity with respect to metabolism (18F-FDG-PET)<br /><br>and hypoxia (18F-FAZA-PET)<br /><br>Correlation between 18F-FAZA-PET/CT identified tumour hypoxic areas and<br /><br>18F-FDG-PET/CT metabolically active areas<br /><br>To investigate metabolic response as assessed by 18F-FDG-PET/CT during<br /><br>treatment<br /><br>To investigate hypoxia response as assessed by 18F-FAZA-PET/CT during treatment </p><br>